Drug Clinical Trials:
News on drug clinical trials, articles on tests or new drugs and medication.
-
Sep 8th, 2008
The Harvard Catalyst is a pan-University collaborative effort committed to harnessing the human, technological, and fiscal resources of Harvard and its academic healthcare centers (AHCs) to reduce the burden of human illness.
-
Aug 29th, 2008
Knowing about financial relationships between medical researchers and the companies that sponsor their studies has little effect on most patients considering enrolling in a clinical trial.
-
Jun 23rd, 2008
Researchers conducting a study to learn if children with a urinary tract disorder known as vesicoureteral reflux should be treated with an antibiotic for an extended period of time are seeking to enroll more participants.
-
Jun 19th, 2008
Peptimmune a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis.
-
Jun 18th, 2008
MEDIHONEY has been found in a large randomized controlled clinical trial to significantly reduce the presence of methicillin-resistant Staphylococcus aureus in chronic wounds.
-
Jun 17th, 2008
In a recently concluded Phase 3 multicenter clinical trial, academic and industry researchers found the use of up to three units of a blood substitute to be relatively safe in patients under 80 with a moderate need for transfusions.
-
Jun 14th, 2008
Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia.
-
Jun 10th, 2008
Results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP with 90Yttrium Ibritumomab Tiuxetan radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma are promising.
-
Jun 6th, 2008
Pharmacyclics announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL).
-
Jun 4th, 2008
Rigel reported an abstract providing preliminary results of a Phase 2 clinical trial of its oral Syk inhibitor, R788, in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas.
